AtaiBeckley Inc (ATAI)
NASDAQHealth CareBiotechnologySnapshot 2026-07-09
$5.17-3.00%
Close 2026-07-10 · 1-day change
Reading ATAI? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading ATAI? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Warn: Management is running behind on a stated commitment.
AtaiBeckley is advancing its clinical programs with a key Phase 3 launch for BPL-003. The company manages operating expenses with operating income near negative $31 million and net income near negative $30 million in 2026-Q1. Analysts have recently revised earnings estimates slightly upward. The stock price has gained 15% over the last 21 days, reflecting improving sentiment.
AtaiBeckley remains unprofitable with ongoing losses and negative free cash flow. Revenue is expected to decline about 54% next year. The company faces litigation and has a history of earnings misses. Clinical-stage biotech risks and cash burn continue to pressure the outlook.
The market expects about a 54% decline in revenue next year and negative earnings. Our view aligns with this cautious outlook, reflecting the challenges of clinical-stage development and ongoing losses.
Breaks if: Phase 3 trial delayed or halted
Breaks if: Operating income or net income improves beyond -$20 million persistently
Continue to manage operating expenses and cash burn as the company advances clinical programs, with operating income and net income remaining negative.
Newly stated in 2026-Q1. The company reported operating income of negative $30.9 million and net income of negative $29.8 million in 2026-Q1, reflecting continued investment and cash burn. No prior quarters in the supplied data restate this priority. The trajectory shows ongoing losses consistent with clinical-stage operations, indicating limited progress on profitability.
“Operating income was negative $30.9 million and net income was negative $29.8 million in 2026-Q1”
Breaks if: Revenue decline exceeds 50% YoY
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.